RIPK1 / Receptor-interacting serine/threonine-protein kinase 1 · IHC design guide

Design Immunohistochemistry for RIPK1

Plan RIPK1 chromogenic IHC in paraffin sections using the cytoplasmic tissue pattern and cell type differences reported by HPA (HPA tissue IHC). Compare staining within defined cell populations and keep fixation consistent across samples (HPA tissue IHC; standard IHC practice).

Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use

Immunohistochemistry protocol sheet for RIPK1 (IHC for RIPK1): expected localisation Cytoplasmic staining (HPA tissue IHC); cell membrane location (UniProt), antibody A00141-1, validated IHC image, and IHC protocol steps — Printable **RIPK1** IHC protocol sheet — expected localisation Cytoplasmic staining (HPA tissue IHC); cell membrane location (UniProt), antibody A00141-1, controls and protocol steps. Open the full RIPK1 IHC guide →

Navigate to: Protocols Staining pattern Controls Antibodies

RIPK1 Immunohistochemistry Experimental Design Guide

Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before staining

	Expected localisation	Cytoplasmic staining (HPA tissue IHC); cell membrane location (UniProt)
	Staining pattern	Ubiquitous cytoplasmic staining; high in selected glandular cells (HPA tissue IHC)
	Antigen retrieval	Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen)
	Positive control ⓘ	Appendix+4 more · see all
	Negative control ⓘ	None in HPA (detected in all 45 tissues); use no-primary + isotype controls

Important caveats

Reasons your staining may differ from the expected pattern.

	Fixation	Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image A00141-1)
	Caveat	Staining intensity varies by tissue cell type (HPA tissue IHC)
	Regulation	No expression regulator annotated (UniProt)
	Isoform / epitope	2 isoforms; check epitope coverage (UniProt)

Section 1

Recommended RIPK1 IHC & IF Protocols

The catalog antibody’s IHC-P protocol is followed by published RIPK1 staining protocols for rat cerebellum (PMC13582310) and mouse spleen (PMC11071064).

Recommended immunohistochemistry (IHC-P) protocol parameters
Sample	Tissue sections; selected-image fixative not specified (standard IHC workflow)
Fixation	Image fixative and duration unreported (datasheet A00141-1); verify before use.
Sectioning	4–5 µm sections on charged slides (standard)
Deparaffinisation	Xylene, graded ethanol series to water (standard)
Antigen retrieval	Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen)
Peroxidase block	3% H2O2, 10 min, room temperature (standard)
Blocking	10% normal serum of the secondary host, 30 min, room temperature (standard)
Primary antibody	Rabbit anti-RIPK1, 2.5 μg/mL (datasheet A00141-1)
Primary incubation	Overnight at 4 °C (standard)
Detection	HRP-polymer secondary, DAB chromogen 5–10 min (standard)
Counterstain	Hematoxylin, blue, dehydrate and mount (standard)
Expected result	RIPK1-positive staining in glandular cells of appendix (HPA tissue IHC: High). HPA tissue profile: Ubiquitous cytoplasmic expression. No signal in the no-primary control.

💡Decision noteFor paraffin sections, start with citrate pH 6.0 retrieval at 95–98 °C for 20 min (page retrieval rule); the cerebellum study used 95 °C for 30 min (PMC13582310).

Section 2

What Is the Expected RIPK1 Staining Pattern?

RIPK1 should appear predominantly in the cytoplasm, with possible membrane-associated signal (UniProt Q13546 subcellular location; HPA: cytoplasmic tissue profile; HPA: plasma membrane and cytosol approved in ICC-IF). In paraffin sections, expect especially strong staining in glandular cells of several digestive tissues and type I alveolar cells in lung (HPA: High). HPA rates the tissue IHC evidence Supported, with medium consistency between staining and RNA data (HPA: reliability).

What am I looking at on my slide?
Cytoplasmic staining is clear in colon or stomach glandular cells, or lung type I alveolar cells; some cells show membrane accentuation.	This fits the reported high-staining cell populations (HPA: High in these cells) and RIPK1 localisation (UniProt Q13546: cytoplasm and cell membrane). Score the relevant cells and compartment separately from surrounding tissue (general IHC practice).
Strong nuclear-only staining dominates while the expected cytoplasmic pattern is absent.	Treat this as a localisation mismatch, not evidence for nuclear RIPK1: the supplied localisation records specify cytoplasm and cell membrane (UniProt Q13546; HPA: approved cytosol and plasma membrane in ICC-IF). Check whether the nuclear colour belongs to counterstain or nonspecific detection (general IHC practice).
An unexpected cell population stains more strongly than the documented positive cells on the same section.	Review cell identity before calling this cross-reactivity: HPA describes ubiquitous cytoplasmic expression and low tissue specificity, so staining outside its High examples can be genuine (HPA: tissue profile; RNA specificity). If staining lacks the expected compartment, assess nonspecific primary binding or endogenous detection activity (general IHC practice).
Colour spreads across stroma, lumina, or most of the section without distinct cellular boundaries.	That distribution is difficult to reconcile with the reported cytoplasmic cellular profile (HPA: tissue IHC). Evaluate background from detection reagents, incomplete blocking, or inadequate washing using appropriate controls (general IHC practice). Background alone cannot establish RIPK1 abundance.
A known-positive glandular or alveolar population has no convincing signal.	First confirm the sampled cell population: HPA reports High staining in appendix, colon, duodenum, gallbladder, rectum, small intestine, and stomach glandular cells, and lung type I alveolar cells (HPA: tissue IHC). A blank result warrants review of the antibody and detection workflow; HPA's Supported rating does not guarantee every specimen will stain (HPA: reliability; general IHC practice).

💡Expected RIPK1 appearanceCall a section positive when identifiable glandular cells in an HPA High digestive tissue, or lung type I alveolar cells, show clear cytoplasmic staining, potentially with membrane accentuation; isolated nuclear colour or diffuse noncellular deposit is not the documented RIPK1 pattern (HPA: High cell populations and cytoplasmic profile; UniProt Q13546: cytoplasm and cell membrane).

How each factor affects the staining
Tissue and cell selection	Use the named High populations as positive references (HPA: tissue IHC). HPA lists low staining in cerebral-cortex endothelial cells, hippocampal and caudate glial cells, adrenal and salivary glandular cells, and liver cholangiocytes; low is not an absence control (HPA: Low; negative list empty).
Subcellular interpretation	RIPK1 has no transmembrane segment, although UniProt lists cell-membrane localisation (UniProt Q13546: topology and subcellular location). Do not require a continuous membrane rim in paraffin sections; HPA describes the tissue pattern as ubiquitous cytoplasmic expression (HPA: tissue profile).
Antibody evidence	HPA lists HPA015257 and CAB010302 as IHC Supported and ICC Approved (HPA: antibody validation). Supported is the supplied status; it does not establish that a different catalog antibody has the same tissue pattern or that either antibody resolves RIPK1 isoforms (HPA: antibody records; UniProt Q13546: two isoforms).
IF/ICC Q&A: Where should signal appear?	Cytosol and plasma membrane are the approved ICC-IF locations, with images listed for A-431, U-251MG, U2OS, and KOLF2.1J (HPA: subcellular). This localisation helps interpret IF images; the tissue-intensity examples come from IHC and should not be assigned to those cell lines (HPA: tissue IHC; HPA: ICC-IF record).
Processing and molecular forms	UniProt reports a single chain spanning residues 1–671, no signal peptide or propeptide, and two isoforms (UniProt Q13546: processing and isoforms). These annotations provide no basis to expect staining of a shed fragment or to predict which isoform an antibody detects without its epitope information.

Why is my staining missing, weak or wrong?
Situation	Likely cause	Next action
The intended positive field looks blank.	The section may lack the specific glandular or type I alveolar cells reported as High, or the staining run may have failed (HPA: High cell populations; general IHC practice).	Verify cell identity and run a documented High tissue alongside the test section; inspect the detection controls and the antibody's IHC-P instructions (HPA: tissue IHC; general IHC practice).
Signal is weak in a cell population listed as Low.	Low staining is already reported for several cell populations and does not imply a true negative (HPA: Low; negative list empty).	Compare with a documented High population in the same run before changing the assay; record intensity by cell type (HPA: High and Low; general IHC practice).
Nuclei appear positive but cytoplasm does not.	The distribution conflicts with the supplied RIPK1 localisation; counterstain or nonspecific colour may be mistaken for target signal (UniProt Q13546; HPA: cytoplasmic profile; general IHC practice).	Review the single-stain and no-primary controls, then assess staining in the expected cytoplasmic compartment (general IHC practice; HPA: tissue profile).
Diffuse brown deposit obscures cell boundaries.	Background from endogenous detection activity, reagent binding, or washing can obscure a cellular pattern (general IHC practice).	Compare no-primary and detection-only controls; check blocking, washing, and detection conditions before assigning a RIPK1 score (general IHC practice).
Membrane accentuation is absent despite clear cytoplasmic staining.	A complete membrane rim is not required by the tissue IHC profile, which reports ubiquitous cytoplasmic expression (HPA: tissue profile).	Score the cytoplasmic signal in the correct cells; use the HPA ICC-IF localisation only as supporting compartment context (HPA: tissue IHC; HPA: approved ICC-IF locations).
Results change after retrieval conditions are adjusted.	The supplied sources do not report RIPK1-specific retrieval or fixation sensitivity (UniProt Q13546; HPA: supplied tissue and subcellular records).	Use the IHC-validated antibody's stated IHC-P conditions as the starting point and compare controls across runs; interpret any condition effect as assay-specific until validated (general IHC practice).

Source: UniProt Q13546 Human Protein Atlas tissue Human Protein Atlas subcellular

Experiment evidence

IHC & IF images showing RIPK1 staining

A00141-1 · IHCImmunohistochemistry of RIPK1 in mouse kidney tissue with RIPK1 antibody at 2.5 μg/mL.

A00141-1 · IHCImmunohistochemistry of RIPK1 in mouse kidney tissue with RIPK1 antibody at 2.5 μg/ml.

A00141-1 · IFImmunofluorescence of RIPK1 in Mouse Kidney cells with RIPK1 antibody at 20 μg/mL.

M00141-3 · IHCRat kidney was stained with Anti-RIP rabbit antibody

M00141-3 · IHCHuman cervical carcinoma was stained with anti-RIP rabbit antibody

A00141 · IHCImmunohistochemistry of RIP1 in human placenta tissue with RIP1 antibody at 10 μg/mL.

HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000137275-RIPK1/tissue/cerebral+cortex#imid_3509928

HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000137275-RIPK1/tissue/colon#imid_3509870

HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000137275-RIPK1/tissue/liver#imid_3509863

HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000137275-RIPK1/tissue/kidney#imid_3509872

HPA · ICC-IF A-431Human Protein Atlas immunofluorescence, A-431, antibody CAB010302; green = RIPK1, blue = nucleus, red = microtubules.

← swipe / scroll for more images →

Real IHC / IF data behind the staining-pattern expectations in this section.

Sample controls for RIPK1 IHC & IF

🧪Run colon first: glandular cells should stain (HPA: High in colon glandular cells). HPA detects RIPK1 in all 45 scored tissues, so there is no supported negative tissue; use no-primary and isotype controls, and treat any unstained cells within the colon section as background references rather than proven RIPK1-negative cells (HPA: no negative tissues).

Positive control tissue: Appendix (Glandular cells, HPA High)

Negative control tissue: None in HPA: RIPK1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.

ICC-IF cell lines (HPA subcellular resource): HPA ICC-IF images show RIPK1 in A-431, U-251MG, U2OS, KOLF2.1J, with annotated localisation: Plasma membrane (approved), Cytosol (approved) (HPA subcellular).

Technical controls: Include a no-primary, secondary-only slide and a control immunoglobulin matched to the primary antibody’s host species, isotype and concentration; a RIPK1-knockout specimen provides a biological specificity control (standard IHC practice). Quench endogenous peroxidase for chromogenic detection and check whether luminal material or inflammatory cells create background in the colon section (standard IHC practice).

⚠️Feasibility: No target-specific fixation window or retrieval dependency is reported in the supplied evidence; optimize antigen retrieval on paraffin sections empirically (standard IHC practice). The selected A00141-1 mouse kidney IHC caption reports staining at 2.5 μg/mL but does not state a fixative (selected product caption). Frozen-section performance and any practical advantage over paraffin IHC are unreported; IF/ICC can assess the plasma membrane and cytosol localization shown by HPA, with tissue autofluorescence checked separately (HPA: approved plasma membrane and cytosol locations; standard IF practice).

HPA tissue IHC evidence for RIPK1

Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Supported — Medium consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

Tissue	Cell type	Level	Evidence	Source
Appendix	Glandular cells	High	Protein (IHC)	HPA →
Colon	Glandular cells	High	Protein (IHC)	HPA →
Duodenum	Glandular cells	High	Protein (IHC)	HPA →
Gallbladder	Glandular cells	High	Protein (IHC)	HPA →
Lung	Alveolar cells type I	High	Protein (IHC)	HPA →

Undetected expression · recommended negative controls

Tissue	Cell type	Level	Evidence	Source
None in HPA: RIPK1 is detected in all 45 scored tissues. Use a no-primary (secondary-only) and an isotype control instead.

Section 3

Advanced RIPK1 IHC Tips

Troubleshoot RIPK1 staining in paraffin sections by checking retrieval, compartment, controls, and scoring before interpreting pathway activity.

How should I retrieve RIPK1 in paraffin sections when cytoplasmic staining is weak?

Start with citrate buffer at pH 6.0, heated to 95–98 °C for 20 min (page antigen retrieval rule). Allow sections to cool in buffer, then compare them with an otherwise identically processed section to judge whether retrieval improves cellular signal (standard IHC practice). RIPK1 is reported in the cytoplasm and at the cell membrane, so assess both compartments rather than demanding a membrane outline (UniProt Q13546 subcellular). If signal remains weak, check the primary antibody concentration and detection controls before changing retrieval conditions (standard IHC practice). Record any revised retrieval condition alongside the original when comparing staining intensity (standard IHC practice).

Could fixation explain weak or uneven RIPK1 staining?

Target-specific sensitivity of RIPK1 staining to fixation is unknown from the supplied evidence; the selected mouse kidney caption does not state a fixative (A00141-1 caption). Document each specimen’s fixative, time in fixative, processing history, and section age before comparing staining across cases (standard IHC practice). Compare sections processed together with the same citrate pH 6.0, 95–98 °C, 20 min retrieval to limit technical variation (page antigen retrieval rule; standard IHC practice). Patchy staining near folds or poorly preserved areas warrants inspection of tissue morphology and a matched control section (standard IHC practice). Do not infer a RIPK1-specific fixation effect from its reported localisation or phosphorylation sites (UniProt Q13546 subcellular and modified residues).

Should RIPK1 stain cytoplasm, membrane, or both?

Expect predominantly cytoplasmic staining in tissue, with possible membrane-associated signal: HPA describes ubiquitous cytoplasmic expression, while its subcellular data place RIPK1 in cytosol and plasma membrane (HPA tissue IHC; HPA subcellular). RIPK1 has no transmembrane segment, so a membrane-associated pattern need not resemble a continuous membrane-spanning marker (UniProt Q13546 topology). At 2.5 µg/mL, the selected catalog image shows RIPK1 IHC in mouse kidney, but its caption does not specify fixation (A00141-1 caption). Judge localisation in intact cells at a consistent magnification, with counterstain and a no-primary control to clarify boundaries and nonspecific deposit (standard IHC practice). Treat isolated nuclear staining cautiously unless supported by an independent specificity control (UniProt Q13546 subcellular; standard IHC practice).

Can this IHC antibody distinguish RIPK1 isoforms or activation states?

RIPK1 has 2 annotated isoforms, but the supplied catalog caption does not identify the antibody’s epitope or establish isoform selectivity (UniProt Q13546 isoforms; A00141-1 caption). Its kinase domain spans residues 17–289 and its death domain 583–669; epitope position could therefore affect which protein forms are detected (UniProt Q13546 domains; standard IHC practice). RIPK1 also carries annotated phosphorylation sites, including serines 161 and 166, but ordinary total-protein staining does not establish phosphorylation state (UniProt Q13546 modified residues; standard IHC practice). Request the antibody’s immunogen or epitope information before assigning a staining difference to an isoform (standard IHC practice). Use an appropriately validated modification-specific assay if the question concerns kinase activation (standard IHC practice).

How can I examine RIPK1 by IF alongside a cell-type marker?

For a separate IF experiment, pair RIPK1 with a validated marker for the cell population under study and include single-label controls to check channel bleed-through (standard IF practice). Choose a far-red fluorophore when tissue autofluorescence obscures shorter-wavelength channels, and inspect an unstained section in every channel (standard IF practice). RIPK1 is reported in cytosol and at the plasma membrane, while its antibody epitope is unspecified; choose permeabilisation only after establishing whether that epitope is accessible without it (HPA subcellular; A00141-1 caption; standard IF practice). Compare paired sections with and without a mild permeabilisation step while keeping fixation and imaging settings constant (standard IF practice). The mouse kidney caption supports tissue IHC at 2.5 µg/mL, not an IF dilution or fixation condition (A00141-1 caption).

How do I reduce diffuse or granular background in RIPK1 IHC?

Because RIPK1 is reported as broadly cytoplasmic in tissue, diffuse cellular signal alone cannot establish that every stained area is specific (HPA tissue IHC; standard IHC practice). Run a no-primary control, block endogenous peroxidase before chromogenic detection, and assess whether deposit remains in vessels, damaged tissue, or section edges (standard IHC practice). Optimise blocking, washes, and the primary concentration against an appropriate positive section; 2.5 µg/mL is the concentration shown in the selected mouse kidney caption (standard IHC practice; A00141-1 caption). Keep DAB development time consistent across compared sections and stop before dense precipitate obscures cell boundaries (standard IHC practice). Use morphology and the control slide to separate cellular staining from pigment or endogenous enzyme signal (standard IHC practice).

What is a defensible way to score RIPK1 across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION

Define the anatomical region and cell population before scoring, then quantify cytoplasmic staining consistently across all compared sections (HPA tissue IHC; standard IHC practice). An H-score combines the percentages of cells assigned intensity 0–3 and ranges from 0–300; report the percentage positive as well when thresholds matter (standard IHC practice). Alternatively, count positive cells per mm² within a predefined viable tissue area, excluding folds, empty space, and necrotic regions (standard IHC practice). Normalise counts to viable area or eligible cells, and compare slides stained in the same run with fixed imaging and scoring settings (standard IHC practice). Report compartment and cell population separately so tissue composition does not masquerade as a RIPK1 change (HPA tissue IHC; standard IHC practice).

When is apparent RIPK1 positivity more likely to be artefact?

A credible pattern should localise mainly to cytoplasm, with possible membrane-associated staining, in morphologically intact cells (HPA tissue IHC; HPA subcellular; standard IHC practice). Question staining confined to nuclei, section edges, folds, or necrotic debris, especially when the no-primary control also develops colour (UniProt Q13546 subcellular; standard IHC practice). Consider cell identity: HPA reports high glandular-cell staining in colon and low glial-cell staining in hippocampus, so compare like cell populations (HPA tissue IHC). Check peroxidase blocking and DAB development when granular deposit appears outside intact cells (standard IHC practice). RIPK1 staining measures antigen distribution; it does not by itself prove kinase activation, apoptosis, or necroptosis (UniProt Q13546 function; standard IHC practice).

Boster reagents

Best RIPK1 / Receptor-interacting serine/threonine-protein kinase 1 IHC Antibodies

Three catalog antibodies have RIPK1 IHC images in human placenta, mouse kidney, or human cervical carcinoma; one also has a mouse kidney cell IF image (catalog image captions).

Real IHC data Immunohistochemistry of RIPK1 in mouse kidney tissue with RIPK1 antibody at 2.5 μg/mL.

Anti-RIPK1 Antibody

Cat # A00141-1

View product →

Real IHC data Rat kidney was stained with Anti-RIP rabbit antibody

Anti-RIP Rabbit Monoclonal Antibody

Cat # M00141-3

View product →

Real IHC data Immunohistochemistry of RIP1 in human placenta tissue with RIP1 antibody at 10 μg/mL.

Anti-RIPK1 Antibody

Cat # A00141

View product →

A00141 shows human placenta IHC at 10 μg/mL (A00141 IHC image caption); A00141-1 shows mouse kidney IHC at 2.5 μg/mL and mouse kidney cell IF at 20 μg/mL (A00141-1 image captions). M00141-3 has IHC captions for rat kidney and human cervical carcinoma, while its listed reactivity is Human only (M00141-3 IHC image captions; catalog reactivity).

Which to pick: For human tissue IHC-P, A00141 has a human placenta image and a listed 5–10 μg/mL range (A00141 IHC image caption; datasheet: IHC-P, 5–10 μg/mL); its fixative is unreported (A00141 IHC image caption). For IF, start with A00141-1 at 20 μg/mL, supported by its mouse kidney cell IF image (A00141-1 IF image caption; datasheet: 20 μg/mL). For work across human, mouse, and rat, A00141-1 lists all three species and IHC-P and IF applications, with mouse kidney IHC evidence; its fixative is unreported (A00141-1 catalog reactivity and applications; IHC image caption).

Each figure is that product's own IHC / IF validation image from its datasheet.

References

UniProt Consortium. UniProt entry Q13546 (RIPK1_HUMAN, Receptor-interacting serine/threonine-protein kinase 1).
Human Protein Atlas. RIPK1 tissue IHC expression (reliability: Supported).
Human Protein Atlas. RIPK1 subcellular location (ICC-IF): Localized to the plasma membrane and cytosol..
Human Protein Atlas. RIPK1 antibody validation summary (2 antibodies).
Impact of Losartan Nanoparticles on Carbon Tetrachloride-induced Cerebellar Injury in Rats: Association with Alterations in RIPK1/RIPK3/MLKL Necroptosis Markers. Molecular neurobiology 2026 — PMC13582310.
Radiosynthesis and characterization of a carbon-11 PET tracer for receptor-interacting protein kinase 1. Nuclear medicine and biology 2022 — PMC11071064.
An immunohistochemical atlas of necroptotic pathway expression. EMBO molecular medicine 2024 — PMC11250867.
Alleviation of temporomandibular joint osteoarthritis by targeting RIPK1-mediated inflammatory signalling. Journal of cellular and molecular medicine 2024 — PMC10902568.
PubMed PMID:8612133 — UniProt-cited evidence.
PubMed PMID:14702039 — UniProt-cited evidence.
PubMed PMID:14574404 — UniProt-cited evidence.